Results 31 to 40 of about 11,886 (196)

Eculizumab-related progressive multifocal leukoencephalopathy [PDF]

, 2015
Progressive multifocal leukoencephalopathy (PML) is an opportunistic infection of the CNS caused by reactivation of the polyomavirus JC (JCV). In the context of immunosuppression, JCV can reactivate and spread to brain infecting oligodendrocytes ...
Ivanovic Barbeito, Yerko, Ramos González, Ana, Gómez Cibera, Emilio, Villarejo Galende, Alberto, Hilario Barrio, Amaya, Gutiérrez Martínez, Eduardo, Abradelo De Usera, Manuel, Ruíz Morales, Juan, Morales Ruiz, Enrique   +8 more
core   +1 more source

Prophylactic or Early Use of Eculizumab and Graft Survival in Kidney Transplant Recipients With Atypical Hemolytic Uremic Syndrome in the United States: Research Letter

Canadian Journal of Kidney Health and Disease, 2021
Introduction: Among kidney transplant recipients (KTRs) with end-stage kidney disease (ESKD) due to atypical hemolytic uremic syndrome (aHUS), recurrence is associated with poor allograft outcomes. We compared graft and patient survival of aHUS KTRs with
Richard A. Plasse, Stephen W. Olson, Christina M. Yuan, Lawrence Y. Agodoa, Kevin C. Abbott, Robert Nee   +5 more
doaj   +1 more source

Life-threatening pregnancy-associated atypical haemolytic uraemic syndrome and its response to eculizumab [PDF]

, 2017
Pregnancy-associated atypical haemolytic uraemic syndrome (P-aHUS) is a rare, potentially lethal condition that can complicate pregnancy in up to 1 in 25 000 cases. Without prompt diagnosis and initiation of appropriate treatment, this condition can lead
Kurtkoti, Jagadeesh, Aye San, Gately, Ryan, Alan Parnham, Parnham, Alan, Ryan Gately, San, Aye, Jagadeesh Kurtkoti   +7 more
core   +1 more source

Data_Sheet_1_Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.PDF [PDF]

, 2021
Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS).
Rachel Millner (11522578), Parthak Prodhan (11522584), Richard Blaszak (11522575), Saritha Ranabothu (11522572), Clare C. Brown (9509210), Kristen Rice Moore (11522581)   +5 more
core   +1 more source

Eculizumab treatment alters the proteometabolome beyond the inhibition of complement

JCI Insight, 2023
Therapeutic strategies targeting complement have revolutionized the treatment of myasthenia gravis (MG). However, a deeper understanding of complement modulation in the human system is required to improve treatment responses and identify off-target ...
Christopher Nelke, Christina B. Schroeter, Frauke Stascheit, Niklas Huntemann, Marc Pawlitzki, Alice Willison, Saskia Räuber, Nico Melzer, Ute Distler, Stefan Tenzer, Kai Stühler, Andreas Roos, Andreas Meisel, Sven G. Meuth, Tobias Ruck   +14 more
doaj   +1 more source

Transplantation in pediatric aHUS within the era of eculizumab therapy [PDF]

, 2021
aHUS is caused by the over-activation and dysregulation of the alternative complement pathway. Data regarding outcomes of pediatric aHUS patients after kidney transplantation are still very scarce.
Fatih Ozaltin, TOPALOĞLU, REZAN, Nur Canpolat, Baskin, Esra, Yuruk Yildirim, Zeynep, Kasap Demir, Belde, ÖZÇAKAR, ZEYNEP BİRSİN, Demircioglu Kilic, Beltinge, Parmaksiz, Gonul, Zeynep Yuruk Yildirim, Oğuz Söylemezoğlu, Zeynep Birsin Özçakar, Elif Çomak, Bora Gülhan, YÜKSEL, SELÇUK, ÇOMAK, ELİF, Gönül Parmaksız, Selçuk Yüksel, ÖZALTIN, FATİH, Beltinge Demircioğlu Kılıç, GÜLHAN, BORA, Canpolat, Nur, Belde Kasap Demir, Soylemezoglu, Oguz, Esra Baskın, Rezan Topaloğlu   +25 more
core   +3 more sources

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Haematologica, 2010
Background Paroxysmal nocturnal hemoglobinuria is an acquired hemolytic anemia characterized by intravascular hemolysis which has been demonstrated to be effectively controlled with eculizumab.
Anita Hill, Russell P. Rother, Louise Arnold, Richard Kelly, Matthew J. Cullen, Stephen J. Richards, Peter Hillmen   +6 more
doaj   +1 more source

Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings [PDF]

, 2011
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy associated with defective regulation of the alternative complement pathway.
Sibylle Tschumi, Tschumi, Sibylle, Simonetti, Giacomo D, Giacomo D. Simonetti, Magdalena Riedl, Barbara S. Bucher, Bucher, Barbara S, Gugger, Mathias, Riedl, Magdalena, Mathias Gugger   +9 more
core   +1 more source

MG rituximab vs eculizumab [PDF]

, 2022
MG rituximab vs eculizumab in a retrospective cohort studyTHIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE.
Nelke, C (via Mendeley Data)
core   +1 more source

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis

Frontiers in Medicine, 2023
Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by genetic abnormalities, infections, autoimmune diseases, drugs, and malignancies.
Sanober Sadiq, Anatoly Urisman, Onur Cil
doaj   +1 more source